Illumina Corporate Foundation
The Illumina Corporate Foundation is the corporate foundation of Illumina, Inc.; its philanthropy and grant programs are described on Illumina’s corporate social responsibility pages and in published CSR reports. Recent IRS filings and public grant records show active grantmaking focused on STEM education, patient access/genetic and rare-disease initiatives and community support, with application/partner portals linked from Illumina pages.
Source: Website · Mar 2026
Ideal Applicant
Nonprofits working in STEM education, genomics/rare-disease patient support, or community/STEM programs (especially in the San Diego/Bay Area), and national intermediaries able to run partnership programs or employee-engagement projects.
Good Fit
- • Projects centered on STEM education, workforce/teacher supports, or public science engagement.
- • Programs related to genetics, rare-disease patient education, or precision-medicine outreach.
- • Capacity to participate in corporate partnership platforms (Benevity/Foundation Source) and to support employee volunteer opportunities.
- • Geographic presence or program activity in California, especially San Diego or the Bay Area, or ability to run scalable national programs.
Geography
In the latest year grants were made across six states but a clear majority of dollars (56%) went to California; past filings show the funder has also supported national and international recipients in other years.
Recipient Variety
The foundation funded 21 distinct recipients in 2024 (15 of them new that year) and prior years include very large recipient counts (over 1,300 recipients in 2022), indicating a broadly distributed portfolio rather than a tiny closed circle.
New Applicants
Direct evidence of entry is visible: a public rolling application via Foundation Source/Benevity plus 15 new grantees in 2024 (about 71% of recipients that year) and three years of filings showing turnover, which together support realistic access for unfamiliar applicants.
Source: Zeffy Agent · Mar 2026
